Collectively, our results indicate that UBE2C-ZEB1/2-ABCG2/ERCC1 reverses DDP resistance by downregulating antidrug genes and reducing EMT in cisplatin-resistant NSCLC cells. The gene discussed is UBE2C; the disease is non-small cell lung carcinoma.